GW1516 (Cardarine)
Synthetic peptide studied in animal and cell models for endurance capacity and lipid profiles
Last updated: March 1, 2026
- Compound
- GW1516 (Cardarine)
- Class
- Body Composition peptide
- Summary
- Synthetic peptide studied in animal and cell models for endurance capacity, lipid profiles, fat metabolism activation.
- Mechanism
- Systemic Metabolic Improvement
- Research Status
- Phase I
- Routes Studied
- Oral administration
- Evidence Level
- Early-stage research · Clinically unproven
What Should You Know About GW1516 (Cardarine)?
- What is GW1516 (Cardarine)?
- GW1516 (Cardarine) is a synthetic peptide studied in animal and cell models for endurance capacity and lipid profiles.
- Is GW1516 (Cardarine) clinically proven?
- No. Human evidence remains limited and does not establish GW1516 (Cardarine) as clinically proven.
- What has GW1516 (Cardarine) been studied for?
- GW1516 (Cardarine) has been studied in preclinical models of endurance capacity, lipid profiles, fat metabolism activation. These findings have not been confirmed in large-scale human trials.
- Is GW1516 (Cardarine) approved?
- No. GW1516 (Cardarine) is not an approved drug and remains a research compound.
What Is GW1516 (Cardarine)?
GW1516, also known as GW501516, Cardarine, or Endurobol, is a synthetic selective agonist of the peroxisome proliferator-activated receptor delta (PPAR-delta), originally developed through a collaboration between GlaxoSmithKline and Ligand Pharmaceuticals in the early 2000s. With the molecular formula C21H18F3NO3S2 and a molecular weight of 453.50 g/mol, GW1516 is a small molecule research compound, not a peptide, steroid, or hormone. It represents a pharmacologically distinct class of metabolic modulators that directly...
Evidence Summary
GW1516 (Cardarine) has early-stage clinical data only. Safety data is emerging but efficacy evidence remains limited. Most claims exceed current clinical evidence.
Evidence Breakdown
| Domain | Evidence Level |
|---|---|
| Endurance Capacity | Limited |
| Lipid Profiles | Limited |
| Fat Metabolism Activation | Limited |
| Anti-Inflammatory Metabolic Effects | Limited |
| Human clinical evidence | Limited |
| Safety data | Insufficient |
Editorial Position
GW1516 (Cardarine) is best understood as a preclinical research compound with promising biological signals but limited human validation. Many online claims exceed the strength of available human evidence, and safety data remains incomplete. Any consideration of this compound should involve careful evaluation of individual context and medical guidance.
Regulatory Status Snapshot
- Not approved as a therapeutic drug by major regulators
- Safety profile not established in large human populations
Need help interpreting this evidence for your situation?
Talk to a SpecialistA deep research review for GW1516 (Cardarine) is not yet available. This compound profile is based on published peer-reviewed references listed below.
Browse all research reviewsWhat Has GW1516 (Cardarine) Been Studied For?
Research areas where GW1516 (Cardarine) has been investigated in published studies
-
Endurance Capacity GW1516 (Cardarine) has been studied in animal models of endurance capacity. These findings have not been confirmed in controlled human trials.
-
Lipid Profiles GW1516 (Cardarine) has been studied in animal models of lipid profiles. These findings have not been confirmed in controlled human trials.
-
Fat Metabolism Activation GW1516 (Cardarine) has been studied in animal models of fat metabolism activation. These findings have not been confirmed in controlled human trials.
-
Anti-Inflammatory Metabolic Effects GW1516 (Cardarine) has been studied in animal models of anti-inflammatory metabolic effects. These findings have not been confirmed in controlled human trials.
How Does GW1516 (Cardarine) Work?
These mechanisms have been observed in preclinical models. They are plausible but have not been linked to proven clinical outcomes in humans.
- 01 PPAR-Delta Receptor Activation
- 02 Fatty Acid Oxidation Gene Transcription
- 03 Metabolic Substrate Switch
- 04 Physiological outcome
Not sure if GW1516 (Cardarine) is right for you?
A specialist can review the evidence, evaluate your medical context, and help you make an informed decision about GW1516 (Cardarine).
Community Reports (Anecdotal)
Experiences shared here are self-reported and do not represent clinical evidence.
Rate GW1516 (Cardarine)
How Is GW1516 (Cardarine) Administered?
GW1516 (Cardarine) is available via Oral administration. Appropriate use and protocol should be determined by a qualified specialist.
What Are the Specifications of GW1516 (Cardarine)?
What Conditions Has GW1516 (Cardarine) Been Linked To?
Have Questions About GW1516 (Cardarine)?
Yes. GW1516 has been prohibited by the World Anti-Doping Agency (WADA) since 2009, classified under S4.5 (Metabolic Modulators). WADA took the unusual step of issuing a direct warning to athletes about GW1516 in 2013 due to safety concerns.
Published studies on GW1516 (Cardarine) can be found on PubMed and other peer-reviewed databases. Our references section below lists key citations.
GW1516 (Cardarine) is available as a research compound in Thailand. Consult a qualified specialist to discuss whether it is appropriate for your needs.
Ready to discuss GW1516 (Cardarine) with a specialist?
Get evidence-based guidance tailored to your health goals and medical context.
Book a Consultation Free initial consultation. No obligation.Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026